Evidence map›Paper›PMID 26893478›Full record

ArticleCancer research2016

In Vivo Visualization and Characterization of Epithelial-Mesenchymal Transition in Breast Tumors.

Zhen Zhao, Xiaoping Zhu, Kemi Cui, James Mancuso, Richard Federley, Kari Fischer, Gaojun Teng, Vivek Mittal, Dingcheng Gao, Hong Zhao and 1 more

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Multidimensional Imaging of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.International journal of molecular sciences · 2021
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Zhen Zhao *Department of Radiology, Zhong-Da Hospital, Southeast University, Nanjing 210009, China.
Xiaoping Zhu *Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
Kemi CuiDepartment of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
James MancusoDepartment of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
Richard FederleyDepartment of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
Kari FischerDepartment of Cell and Developmental Biology, Weill Cornell Medicine, New York 10065, USA.
Gaojun TengDepartment of Radiology, Zhong-Da Hospital, Southeast University, Nanjing 210009, China.
Vivek MittalDepartment of Cell and Developmental Biology, Weill Cornell Medicine, New York 10065, USA.
Dingcheng GaoDepartment of Cell and Developmental Biology, Weill Cornell Medicine, New York 10065, USA.
Hong ZhaoDepartment of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
Stephen Tc WongDepartment of Systems Medicine and Bioengineering, Houston Methodist Research Institute, Weill Cornell Medicine, Houston, TX 77030, USA.
Houston Methodist · USCornell University · USZhongda Hospital Southeast University · CN

Funding

The Core of the Computational BiologyU54CA149196 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WONG, STEPHEN TC · 2010 to 2015
$10.6M
Modeling tumor-stroma crosstalk in lung cancer to identify targets for therapyU01CA188388 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI MITTAL, VIVEK, WONG, STEPHEN TC · 2015 to 2019
$2.5M
NCI NIH HHS U01 CA188388NCI NIH HHS U54 CA149196
6 · The paper itself

Abstract

The activation of the epithelial-to-mesenchymal transition (EMT) program is a critical step in cancer progression and metastasis, but visualization of this process at the single-cell level, especially in vivo, remains challenging. We established an in vivo approach to track the fate of tumor cells based on a novel EMT-driven fluorescent color switching breast cancer mouse model and intravital two-photon laser scanning microscopy. Specifically, the MMTV-PyMT, Rosa26-RFP-GFP, and Fsp1-Cre triple transgenic mouse model was used to monitor the conversion of RFP-positive epithelial cells to GFP-positive mesenchymal cells in mammary tumors under the control of the Fsp1 (ATL1) promoter, a gate-keeper of EMT initiation. RFP-positive cells were isolated from the tumors, sorted, and transplanted into mammary fat pads of SCID mice to monitor EMT during breast tumor formation. We found that the conversion from RFP- to GFP-positive and spindle-shaped cells was a gradual process, and that GFP-positive cells preferentially localized close to blood vessels, independent of tumor size. Furthermore, cells undergoing EMT expressed high levels of the HGF receptor, c-Met, and treatment of RFP-positive cells with the c-Met inhibitor, cabozantinib, suppressed the RFP-to-GFP conversion in vitro Moreover, administration of cabozantinib to mice with palpable RFP-positive tumors resulted in a silent EMT phenotype whereby GFP-positive cells exhibited reduced motility, leading to suppressed tumor growth. In conclusion, our imaging technique provides a novel opportunity for visualizing tumor EMT at the single-cell level and may help to reveal the intricacies underlying tumor dynamics and treatment responses. Cancer Res; 76(8); 2094-104. ©2016 AACR.

Indexed as

Epithelial-Mesenchymal TransitionAnimalsDisease Models, AnimalFemaleMammary Neoplasms, ExperimentalMiceMice, SCIDMice, TransgenicMicroscopy, Fluorescence

Identifiers

PMID26893478
PMCPMC4873431
OpenAlexW2280089777

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.